Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection.
In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV-1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11% decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.
Wallace
M R
MR
U.S. Naval Medical Center-San Diego, California, USA.
Moss
R B
RB
Beecham
H J
HJ
Grace
C J
CJ
Hersh
E M
EM
Peterson
E
E
Murphy
R
R
Shepp
D H
DH
Siegal
F P
FP
Turner
J L
JL
Safrin
S
S
Carlo
D J
DJ
Levine
A M
AM
D015526:AIDS Dementia Complex / Q000150:complications; D016915:AIDS Vaccines / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic; D015415:Biomarkers; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002180:Candidiasis, Oral / Q000150:complications; D015331:Cohort Studies; D018450:Disease Progression; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006679:HIV Seropositivity / Q000150:complications / Q000276:immunology* / Q000628:therapy; D006566:Herpesviridae Infections / Q000150:complications; D006801:Humans; D017733:Leukoplakia, Hairy / Q000150:complications; D010523:Peripheral Nervous System Diseases / Q000150:complications; D012514:Sarcoma, Kaposi / Q000150:complications; D015164:Vaccines, Inactivated / Q000627:therapeutic use
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015415:Biomarkers; D015164:Vaccines, Inactivated